PAQR6 as a prognostic biomarker and potential therapeutic target in kidney renal clear cell carcinoma

BackgroundProgestin And AdipoQ Receptor Family Member VI (PAQR6) plays a significant role in the non-genomic effects of rapid steroid responses and is abnormally expressed in various tumors. However, its biological function in kidney renal clear cell carcinoma (KIRC) and its potential as a therapeut...

Full description

Saved in:
Bibliographic Details
Main Authors: Tao Zou, Zongming Jia, Jixiang Wu, Xuxu Liu, Minghao Deng, Xuefeng Zhang, Yuxin Lin, Jigen Ping
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1521629/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850251795276759040
author Tao Zou
Zongming Jia
Jixiang Wu
Xuxu Liu
Minghao Deng
Xuefeng Zhang
Yuxin Lin
Yuxin Lin
Jigen Ping
author_facet Tao Zou
Zongming Jia
Jixiang Wu
Xuxu Liu
Minghao Deng
Xuefeng Zhang
Yuxin Lin
Yuxin Lin
Jigen Ping
author_sort Tao Zou
collection DOAJ
description BackgroundProgestin And AdipoQ Receptor Family Member VI (PAQR6) plays a significant role in the non-genomic effects of rapid steroid responses and is abnormally expressed in various tumors. However, its biological function in kidney renal clear cell carcinoma (KIRC) and its potential as a therapeutic target remain underexplored.MethodsIn this study, PAQR6 was identified as a critical oncogene by WGCNA algorithm and differential gene expression analysis using TCGA - KIRC and GSE15641 data. The differences in PAQR6 expression and its association with KIRC survival outcomes were investigated, and transcriptomic data were used to further elucidate PAQR6’s biological functions. Moreover, XCELL and single - cell analysis assessed the correlation between PAQR6 expression and immune infiltration. TIDE algorithm was used to assess how well various patient cohorts responded to immune checkpoint therapy. Finally, the role of PAQR6 in the development of KIRC was verified through EdU, scratch assays, and Transwell assays.ResultsOur findings suggest that elevated expression of PAQR6 is linked to a poor prognosis for KIRC patients. Functional enrichment analysis demonstrated that PAQR6 is primarily involved in angiogenesis and pluripotent stem cell differentiation, which are crucial in mediating the development of KIRC. Additionally, we established a ceRNA network that is directly related to overall prognosis, further supporting the role of PAQR6 as a prognostic biomarker for KIRC.ConclusionUsing both computational and experimental methods, this study leads the charge in discovering and verifying PAQR6 as a prognostic biomarker and possible therapeutic target for KIRC. In the future, to determine its molecular mechanism in KIRC carcinogenesis, more in vivo research will be carried out.
format Article
id doaj-art-251545d558e440c1875922dfd0daf289
institution OA Journals
issn 1664-3224
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-251545d558e440c1875922dfd0daf2892025-08-20T01:57:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.15216291521629PAQR6 as a prognostic biomarker and potential therapeutic target in kidney renal clear cell carcinomaTao Zou0Zongming Jia1Jixiang Wu2Xuxu Liu3Minghao Deng4Xuefeng Zhang5Yuxin Lin6Yuxin Lin7Jigen Ping8Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Neurology Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, ChinaDepartment of Urology, Nantong Hospital of Traditional Chinese Medicine, Nantong, ChinaDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaCenter for Systems Biology, Soochow University, Suzhou, ChinaDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaBackgroundProgestin And AdipoQ Receptor Family Member VI (PAQR6) plays a significant role in the non-genomic effects of rapid steroid responses and is abnormally expressed in various tumors. However, its biological function in kidney renal clear cell carcinoma (KIRC) and its potential as a therapeutic target remain underexplored.MethodsIn this study, PAQR6 was identified as a critical oncogene by WGCNA algorithm and differential gene expression analysis using TCGA - KIRC and GSE15641 data. The differences in PAQR6 expression and its association with KIRC survival outcomes were investigated, and transcriptomic data were used to further elucidate PAQR6’s biological functions. Moreover, XCELL and single - cell analysis assessed the correlation between PAQR6 expression and immune infiltration. TIDE algorithm was used to assess how well various patient cohorts responded to immune checkpoint therapy. Finally, the role of PAQR6 in the development of KIRC was verified through EdU, scratch assays, and Transwell assays.ResultsOur findings suggest that elevated expression of PAQR6 is linked to a poor prognosis for KIRC patients. Functional enrichment analysis demonstrated that PAQR6 is primarily involved in angiogenesis and pluripotent stem cell differentiation, which are crucial in mediating the development of KIRC. Additionally, we established a ceRNA network that is directly related to overall prognosis, further supporting the role of PAQR6 as a prognostic biomarker for KIRC.ConclusionUsing both computational and experimental methods, this study leads the charge in discovering and verifying PAQR6 as a prognostic biomarker and possible therapeutic target for KIRC. In the future, to determine its molecular mechanism in KIRC carcinogenesis, more in vivo research will be carried out.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1521629/fullkidney renal clear cell carcinomaimmune infiltrationprognostic biomarkerPAQR6angiogenesis
spellingShingle Tao Zou
Zongming Jia
Jixiang Wu
Xuxu Liu
Minghao Deng
Xuefeng Zhang
Yuxin Lin
Yuxin Lin
Jigen Ping
PAQR6 as a prognostic biomarker and potential therapeutic target in kidney renal clear cell carcinoma
Frontiers in Immunology
kidney renal clear cell carcinoma
immune infiltration
prognostic biomarker
PAQR6
angiogenesis
title PAQR6 as a prognostic biomarker and potential therapeutic target in kidney renal clear cell carcinoma
title_full PAQR6 as a prognostic biomarker and potential therapeutic target in kidney renal clear cell carcinoma
title_fullStr PAQR6 as a prognostic biomarker and potential therapeutic target in kidney renal clear cell carcinoma
title_full_unstemmed PAQR6 as a prognostic biomarker and potential therapeutic target in kidney renal clear cell carcinoma
title_short PAQR6 as a prognostic biomarker and potential therapeutic target in kidney renal clear cell carcinoma
title_sort paqr6 as a prognostic biomarker and potential therapeutic target in kidney renal clear cell carcinoma
topic kidney renal clear cell carcinoma
immune infiltration
prognostic biomarker
PAQR6
angiogenesis
url https://www.frontiersin.org/articles/10.3389/fimmu.2024.1521629/full
work_keys_str_mv AT taozou paqr6asaprognosticbiomarkerandpotentialtherapeutictargetinkidneyrenalclearcellcarcinoma
AT zongmingjia paqr6asaprognosticbiomarkerandpotentialtherapeutictargetinkidneyrenalclearcellcarcinoma
AT jixiangwu paqr6asaprognosticbiomarkerandpotentialtherapeutictargetinkidneyrenalclearcellcarcinoma
AT xuxuliu paqr6asaprognosticbiomarkerandpotentialtherapeutictargetinkidneyrenalclearcellcarcinoma
AT minghaodeng paqr6asaprognosticbiomarkerandpotentialtherapeutictargetinkidneyrenalclearcellcarcinoma
AT xuefengzhang paqr6asaprognosticbiomarkerandpotentialtherapeutictargetinkidneyrenalclearcellcarcinoma
AT yuxinlin paqr6asaprognosticbiomarkerandpotentialtherapeutictargetinkidneyrenalclearcellcarcinoma
AT yuxinlin paqr6asaprognosticbiomarkerandpotentialtherapeutictargetinkidneyrenalclearcellcarcinoma
AT jigenping paqr6asaprognosticbiomarkerandpotentialtherapeutictargetinkidneyrenalclearcellcarcinoma